PureTech Health PLC

PRTC

Company Profile

  • Business description

    PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

  • Contact

    6 Tide Street
    Suite 400
    BostonMA02210
    USA

    T: +1 617 482-2333

    E: [email protected]

    https://www.puretechhealth.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    90

Stocks News & Analysis

stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.
stocks

ChatGPT enters the retail space and one company surges

Investors cheer the ability to purchase directly from ChatGPT.
stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,136.6015.100.17%
CAC 407,966.9571.010.90%
DAX 4024,113.62232.900.98%
Dow JONES (US)46,418.4920.600.04%
FTSE 1009,446.4396.001.03%
HKSE26,855.56232.680.87%
NASDAQ22,730.3070.290.31%
Nikkei 22544,550.85381.78-0.85%
NZX 50 Index13,433.99141.631.07%
S&P 5006,702.6714.210.21%
S&P/ASX 2008,845.7012.300.14%
SSE Composite Index3,882.7820.250.52%

Market Movers